![\"Brain](\"https:\/\/scitechdaily.com\/images\/Brain-Cancer-Cells-Neurons.jpg\")
<\/a>Centered ultrasound helped ship microRNAs that focused a number of glioblastoma genes and improved outcomes in animal fashions.<\/strong><\/p>\n A remedy geared toward glioblastoma should first cross one of many physique\u2019s most selective defenses: the blood-brain barrier. Researchers on the College of Virginia Complete Most cancers Heart are testing a approach to briefly open that barrier and ship genetic molecules able to suppressing a number of drivers of the most cancers without delay.<\/p>\n The experimental technique targets glioblastoma, the most typical and deadliest type of mind most cancers. Roger Abounader, MD, PhD, and his colleagues at UVA recognized \u201cmicroRNAs,\u201d or miRNAs, that may cut back the exercise of a number of malfunctioning genes concerned within the tumor\u2019s improvement and development.<\/p>\n To hold these molecules into the mind, the researchers mix brain-penetrating nanoparticles with targeted ultrasound and microscopic bubbles. The strategy is designed to maneuver the miRNAs by way of the mind\u2019s protecting barrier, which normally prevents many therapies for tumors and neurodegenerative illnesses from reaching their targets.<\/p>\n \u201cThis new strategy might assist goal quite a few molecules that promote most cancers development, together with these for which no medication exist, on the similar time to realize higher therapies,\u201d mentioned Abounader, a professor at UVA\u2019s Faculty of Medication, Division of Microbiology Immunology and Most cancers Biology, Complete Most cancers Heart and Heart for RNA<\/span> Science and Medicine. \u201cWe are hoping to translate our findings into future clinical trials for patients with glioblastoma and other brain tumors.\u201d<\/p>\n Glioblastoma is the most common and aggressive malignant brain tumor in adults and kills more than 13,000 people in the United States each year. Its cells spread through surrounding healthy brain tissue, making complete surgical removal extremely difficult.<\/p>\n Treatment is further complicated by the blood-brain barrier. This natural defense shields the brain from toxins and infections circulating in the bloodstream, but it also prevents many anti-tumor drugs from entering brain tissue.<\/p>\n Current care usually begins with surgery to remove as much of the tumor as possible. Doctors then use radiation and chemotherapy to extend survival, but the cancer remains exceptionally difficult to control.<\/p>\n Abounader\u2019s approach uses miRNAs, tiny pieces of genetic material that regulate gene activity. Delivering selected miRNAs could allow doctors to suppress several faulty genes simultaneously, slowing or stopping tumor growth by interfering with multiple biological pathways that sustain the cancer.<\/p>\n Conventional treatments struggle to accomplish the same task. Combining several cancer drugs can create harmful toxicity, and many of the molecules that promote glioblastoma growth do not have drugs capable of targeting them.<\/p>\n The researchers would deliver the miRNAs with focused ultrasound guided by magnetic resonance imaging (MRI). The concentrated sound waves direct tiny \u201cmicrobubbles\u201d to a specific location, temporarily opening the blood-brain barrier long enough for nanoparticles carrying the miRNAs to pass through.<\/p>\n In laboratory testing, the miRNA treatment slowed tumor growth and extended survival in animal models of glioblastoma. The approach will require additional study before it can be evaluated in people, but Abounader believes the findings support further investigation in glioblastoma and potentially other cancers.<\/p>\n \u201cThis approach could have broad applications for several brain and other human diseases,\u201d Abounader said. \u201cWe and many others are intensively working to lighten the burden of cancer, and hopefully also completely cure it, but this requires a continued investment in cancer and medical research.\u201d<\/p>\n UVA Health was among the earliest institutions to explore focused ultrasound. Its experience with the technology has grown into a wider research program investigating how focused ultrasound might be used against a range of medical conditions.<\/p>\n UVA and the Charlottesville-based Focused Ultrasound Foundation also established the Focused Ultrasound Immuno-Oncology (FUSION) Center. It is the world\u2019s first center devoted specifically to studying how focused ultrasound could be combined with cancer immunotherapy, an approach experts hope will improve cancer treatment.<\/p>\n Developing new forms of patient care is also a central goal of UVA Comprehensive Cancer Center and UVA\u2019s Paul and Diane Manning Institute of Biotechnology. UVA Comprehensive Cancer Center is one of 57 centers in the United States to hold the National Cancer Institute\u2019s \u201ccomprehensive\u201d designation, which recognizes its cancer research and patient care.<\/p>\n The Manning Institute was created to speed the development of medicines and treatments for difficult diseases. A statewide clinical trials network complements that effort by expanding access to experimental treatments as they move through development and testing.<\/p>\n Reference: \u201cDiscovery and therapeutic delivery of microRNAs targeting deregulated glioblastoma pathways inhibits tumor growth in mice\u201d by Shekhar Saha, Ying Zhang, Myron K. Gibert Jr., Collin Dube, Farina Hanif, Elizabeth Qian Xu Mulcahy, Sylwia Bednarek, Yunan Sun, Pawel Marcinkiewicz, Xiantao Wang, Gijung Kwak, Ahsan H. Polash, Haolin Li, Kadie Hudson, Manikarna Dinda, Tapas Saha, Matthew McCord, Fadila Guessous, Nichola Cruickshanks, Rossymar Rivera Colon, Lily Dell\u2019Olio, Rajitha Anbu, Wenjie Liu, Songy Choi, Benjamin Kefas, Pankaj Kumar, Alexander L. Klibanov, David Schiff, Jung Soo Suk, Justin Hanes, Jamie Mata, Markus Hafner and Roger Abounader, 30 June 2026, The Journal of Clinical Investigation<\/i>. The research was supported by the National Institutes of Health<\/span>\u2019s National Cancer Institute, grants U01 CA220841 and P30 CA044579; the NIH\u2019s National Institute of Neurological Disorders and Stroke, grants R01 NS122222 and R21 NS122136; a UVA Comprehensive Cancer Center pilot grant; a Schiff Foundation grant; the Ben and Catherine Ivy Foundation; and the Focused Ultrasound Foundation.<\/p>\n Never miss a breakthrough: Join the SciTechDaily newsletter.<\/a><\/b><\/a>The blood-brain barrier blocks drugs<\/h4>\n
MicroRNAs target several cancer genes<\/h4>\n
Animal tests show early promise<\/h4>\n
Focused ultrasound expands cancer research<\/h4>\n
DOI: 10.1172\/JCI195639<\/a><\/p>\n
Follow us on Google<\/a> and Google News<\/a>.<\/b><\/p>\n<\/div>\n